Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

BACKGROUND: Lung cancer is one of the most frequent cancer types and the leading cause of cancer death worldwide. Cisplatin is a widely used chemotherapeutic for non-small cell lung carcinoma (NSCLC), however, its positive effects are diminished under hypoxia. We wanted to determine if co-treatment...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Cancer
Main Authors: Fischer, Carina, Leithner, Katharina, Wohlkoenig, Christoph, Quehenberger, Franz, Bertsch, Alexandra, Olschewski, Andrea, Olschewski, Horst, Hrzenjak, Andelko
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4320451/
https://ncbi.nlm.nih.gov/pubmed/25608569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-14-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados